Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial - Agarwal, R; Rossignol, P; Romero, A (Lancet, 2019)
et al.